Literature DB >> 18057527

Immune prognostic factors in ovarian cancer: lessons from translational research.

Phyllis A Gimotty1, Lin Zhang, Ioannis Alagkiozidis, Mark Cadungog, Sarah Adams, Christina Chu, Dionysios Katsaros, George Coukos.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 18057527      PMCID： PMC3851646          DOI： 10.1155/2007/508350

Source DB:  PubMed          Journal:  Dis Markers        ISSN： 0278-0240            Impact factor:   3.434


× No keyword cloud information.
  4 in total

1.  Prognostic impact of lymphocytes in soft tissue sarcomas.

Authors:  Sveinung W Sorbye; Thomas Kilvaer; Andrej Valkov; Tom Donnem; Eivind Smeland; Khalid Al-Shibli; Roy M Bremnes; Lill-Tove Busund
Journal:  PLoS One       Date:  2011-01-27       Impact factor: 3.240

2.  Transimmunization restores immune surveillance and prevents recurrence in a syngeneic mouse model of ovarian cancer.

Authors:  Ayesha B Alvero; Douglas Hanlon; Mary Pitruzzello; Renata Filler; Eve Robinson; Olga Sobolev; Roslyn Tedja; Alessandra Ventura; Marcus Bosenberg; Patrick Han; Richard L Edelson; Gil Mor
Journal:  Oncoimmunology       Date:  2020-05-13       Impact factor: 8.110

3.  Systematic analysis of immune infiltrates in high-grade serous ovarian cancer reveals CD20, FoxP3 and TIA-1 as positive prognostic factors.

Authors:  Katy Milne; Martin Köbel; Steven E Kalloger; Rebecca O Barnes; Dongxia Gao; C Blake Gilks; Peter H Watson; Brad H Nelson
Journal:  PLoS One       Date:  2009-07-29       Impact factor: 3.240

4.  Tumor-infiltrating T cells correlate with NY-ESO-1-specific autoantibodies in ovarian cancer.

Authors:  Katy Milne; Rebecca O Barnes; Adam Girardin; Melanie A Mawer; Nancy J Nesslinger; Alvin Ng; Julie S Nielsen; Robert Sahota; Eric Tran; John R Webb; May Q Wong; Darin A Wick; Andrew Wray; Elissa McMurtrie; Martin Köbel; Steven E Kalloger; C Blake Gilks; Peter H Watson; Brad H Nelson
Journal:  PLoS One       Date:  2008-10-15       Impact factor: 3.240
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.